Increased alpha power in basal ganglia and thalamus following levodopa administration in a dystonic young adult
Objective: To evaluate effects of acute levodopa administration on frequency content of intracranial local field potentials in a dystonic young adult. Background: Levodopa is the…Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…Safety of foslevodopa/foscarbidopa during optimization and maintenance treatment: Post hoc analysis of a phase 3, single-arm trial
Objective: Evaluate the frequency of adverse events over time with foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (PD) in a phase 3, open-label safety…Functional movement disorders in dopa-responsive dystonia – A case series with implications for diagnosis and treatment
Objective: A detailed clinical characterization of functional movement disorders (FMD) in dopa-responsive dystonia (DRD) patients. Background: FMD are one of the most common conditions in…Motor function in Parkinson´s disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa
Objective: To compare the effect of intravenous (DIZ101) and subcutaneous (DIZ102) continuous 16h infusion of a continuously buffered acidic levodopa/carbidopa solution with levodopa/carbidopa intestinal gel…Sex differences in motor response to levodopa in early Parkinson’s disease
Objective: To evaluate differences between males and females in trajectory of motor response to levodopa in early Parkinson’s disease (PD). Background: Previous research has shown…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia
Objective: To determine the distribution and density of metabotropic glutamate 2 (mGlu2) receptors in the motor loop of the basal ganglia in 6-hydroxydopamine (6-OHDA)-lesioned rats…Can very early levodopa prevent self-injury in Lesch-Nyhan Disease?
Objective: To determine whether levodopa treatment starting at a very young age can prevent the development of the full clinical phenotype in Lesch-Nyhan disease. Background:…Effect of differences in stomach and small intestine pH on response to levodopa in patients with Parkinson’s Disease.
Objective: To examine levels of stomach and small intestine (SI) pH in relation to variable clinical responses to doses of levodopa in Parkinson’s disease (PD)…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 62
- Next Page »